Skip to main content
SpringerLink
Log in

Manage paediatric hypertension with lifestyle changes and, if required, appropriate antihypertensive drugs

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Paediatric hypertension is an increasingly common problem, but one that is under recognized and undertreated. Once the condition is accurately assessed, most children should begin therapeutic lifestyle changes (e.g. diet and exercise). If required, pharmacological treatment should be prescribed according to the needs of the individual child and the underlying cause of hypertension. Urgent acute antihypertensive therapy may be warranted in children with severe hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Misurac J, Nichols KR, Wilson AC. Pharmacologic management of pediatric hypertension. Pediatr Drugs. 2016;18(1):31–43.

    Article  Google Scholar 

  2. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.

  3. Flynn J, Zhang Y, Solar-Yohay S, et al. Clinical and demographic characteristics of children with hypertension. Hypertension. 2012;60(4):1047–54.

    Article  CAS  PubMed  Google Scholar 

  4. Dobson CP, Eide M, Nylund CM. Hypertension prevalence, cardiac complications, and antihypertensive medication use in children. J Pediatr. 2015;167(1):92-7.e1.

  5. Lurbe E, Cifkova R, Jk Cruickshank, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719–42.

    Article  CAS  PubMed  Google Scholar 

  6. Juhola J, Oikonen M, Magnussen CG, et al. Childhood physical, environmental, and genetic predictors of adult hypertension: the cardiovascular risk in young Finns study. Circulation. 2012;126(4):402–3.

    Article  PubMed  Google Scholar 

  7. Chaturvedi S, Lipszyc DH, Licht C, et al. Pharmacological interventions for hypertension in children. Evid Based Child Health. 2014;9(3):498–580.

    Article  PubMed  Google Scholar 

  8. Flynn JT, Nahata MC, Mahan JD Jr, et al. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905–16.

    Article  CAS  PubMed  Google Scholar 

  9. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60(2):444–50.

    Article  CAS  PubMed  Google Scholar 

  10. Bitkin EC, Boyraz M, Taşkin N, et al. Effects of ACE inhibitors on insulin resistance and lipid profile in children with metabolic syndrome. J Clin Res Pediatr Endocrinol. 2013;5(3):164–9.

    Article  PubMed  Google Scholar 

  11. Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870–80.

    Article  CAS  PubMed  Google Scholar 

  12. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.

    Article  CAS  PubMed  Google Scholar 

  13. Shaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens. 2013;31(5):993–1000.

    Article  Google Scholar 

  14. López-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341–62.

    Article  PubMed  Google Scholar 

  15. Batisky DL, Sorof JM, Sugg J, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150(2):134–9.

    Article  CAS  PubMed  Google Scholar 

  16. Okeke CC, Medwick T, Nairn G, et al. Stability of hydralazine hydrochloride in both flavored and non-flavored extemporaneous preparations. Int J Pharm Compd. 2003;7(4):313–9.

    PubMed  Google Scholar 

  17. Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol. 2009;24(6):1101–12.

    Article  PubMed  Google Scholar 

  18. Flynn J, Bradford M, Harvey E. Intravenous (IV) hydralazine in hypertensive pediatric in patients: does it work? Is it safe? J Am Soc Hypertens. 2014;8(4 Suppl):e130.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Pediatric Drugs 2016;18(1):31–43 [1] by salaried/contracted employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Manage paediatric hypertension with lifestyle changes and, if required, appropriate antihypertensive drugs. Drugs Ther Perspect 32, 428–433 (2016). https://doi.org/10.1007/s40267-016-0322-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-016-0322-5

    Keywords

    Search

    Navigation